Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Due to system maintenance, login and edit functionaility is currently unavailable

GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML)

GM-CSF Priming with successive concomitant therapy with low-dose ARA-C for older patients with advanced myelodysplastic syndrome (MDS), secondary or refractory acute myeloid leukemia (AML). Am Society of Hematology. 1998.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.